Semaglutide
approvedAlso known as: Ozempic, Wegovy, Rybelsus, NN9535
**Mechanism of Action** Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native GLP-1. It binds to and activates GLP-1 receptors in pancreatic beta cells, enhancing glucose-dependent insulin secretion while suppressing glucagon release. Additionally, it delays gastric emptying and acts on hypothalamic appetite centers to reduce caloric intake, leading to weight loss. Its extended half-life (~1 week) is achieved through albumin binding and resistance to dipeptidyl peptidase-4 (DPP-4) degradation. **Key Research Findings** Clinical trials (e.g., SUSTAIN, PIONEER, STEP) demonstrate that semaglutide significantly reduces HbA1c (1.5–1.8%) and fasting plasma glucose in type 2 diabetes. In obesity trials (STEP 1–4), subcutaneous semaglutide 2.4 mg/week produced mean weight loss of 14.9% over 68 weeks vs. 2.4% with placebo. Cardiovascular outcome trials (SELECT) showed a 20% reduction in major adverse cardiovascular events in overweight/obese patients without diabetes. Common adverse effects include nausea, vomiting, and diarrhea, with rare risks of pancreatitis and gallbladder disease. **Clinical Relevance** Approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), semaglutide is a first-line GLP-1 receptor agonist for glycemic control and obesity treatment. Its once-weekly dosing and proven cardiovascular benefits position it as a cornerstone therapy, though cost and gastrointestinal tolerability limit access. Ongoing research explores its role in non-alcoholic steatohepatitis (NASH) and neurodegenerative diseases. For research purposes only — not medical advice.
Key data
C187H291N45O59Research & studies
Semaglutide resulted in an 11.85% greater mean weight reduction than placebo.; Risk of gastrointestinal adverse events was 1.59 times higher with semaglutide.; Discontinuation due to adverse events was twice as likely with semaglutide.; Serious adverse events, mainly gastrointestinal and hepatobiliary disorders, were 1.6 times more likely with semaglutide.
Frequently asked questions
What is Semaglutide?
**Mechanism of Action** Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native GLP-1. It binds to and activates GLP-1 receptors in pancreatic beta cells, enhancing glucose-dependent insulin secretion while suppressing glucagon release. Additionally, it delay
How does Semaglutide work?
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
What is the research status of Semaglutide?
Semaglutide is currently classified as approved, with 4,814 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Semaglutide?
The reported half-life of Semaglutide is ~7 days.
What is the molecular weight of Semaglutide?
Semaglutide has a molecular weight of approximately 4114 g/mol (formula C187H291N45O59).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Semaglutide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key